Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.
Chen Huei LeoHooi Hooi NgSarah A MarshallMaria JelinicThusitha RupasingheChengxue Helena QinUte RoessnerRebecca H RitchieMarianne TareLaura J ParryPublished in: British journal of pharmacology (2019)
Relaxin has region-dependent vasoprotective actions in hypertension. Specifically, relaxin has distinct effects on endothelium-derived contracting factors and their associated vasoconstrictor pathways in mesenteric arteries and the aorta. Taken together, these observations reveal the potential of relaxin as a new therapeutic agent for vascular disorders that are associated with endothelium-derived vasoconstriction including hypertension.